Search results
Results from the WOW.Com Content Network
Dengue vaccine is a vaccine used to prevent dengue fever in humans. [9] Development of dengue vaccines began in the 1920s but was hindered by the need to create immunity against all four dengue serotypes. [10] As of 2023, there are two commercially available vaccines, sold under the brand names Dengvaxia and Qdenga. [11] [12]
Dengue is spread by several species of female mosquitoes of the Aedes genus, principally Aedes aegypti. [1] Infection can be prevented by mosquito elimination and the prevention of bites. [12] Two types of dengue vaccine have been approved and are commercially available.
The World Health Organization said officials have prequalified a new vaccine for dengue, a virus spread by mosquitoes largely in countries with tropical climates.. The U.S. Centers for Disease ...
Dengue virus (DENV) is the cause of dengue fever.It is a mosquito-borne, single positive-stranded RNA virus of the family Flaviviridae; genus Flavivirus. [1] [2] Four serotypes of the virus have been found, and a reported fifth has yet to be confirmed, [3] [4] [5] all of which can cause the full spectrum of disease. [1]
Meanwhile, in countries where dengue was already endemic, this year has seen the virus spread at an unprecedented scale. ... There are currently two dengue vaccines commercially available: ...
Experts say that the climate is ideal for mosquitoes that can carry the virus to reproduce and continue to spread dengue. ... There is a dengue vaccine for children aged 9 to sixteen if they have ...
In May 2024, TAK-003 became the second dengue vaccine to be prequalified by the World Health Organization (WHO). [47] This live-attenuated vaccine, developed by Takeda is similar to the Dengvaxia vaccine in the fact that it contains a weakened version of the four variants of dengue virus. The difference between the two vaccines is the TAK-003 ...
Takeda's vaccine was 80.2% effective at preventing dengue among children and teens in the year after they got the shot, according to results of a Phase III study published in the New England ...